Skip to main content

Table 1 Baseline characteristics (demographic, clinical, laboratory, ultrasonographic, and pre-study medications) of both groups

From: The efficacy and safety of direct-acting antiviral drugs in the management of hepatitis C virus-related arthritis

Baseline characteristics

Group I (n = 20)

Group 1I (n = 20)

p

Age (mean ± SD)

43.5 ± 7.4

43.8 ± 7.2

0.19

Male: female (n, %)

10(50):10(50)

9 (45):11 (55)

0.75

Disease duration (mean ± SD)

3.1 ± 1.6

3.0 ± 1.4

0.95

RF titer (mean ± SD)

101.2 ± 76.2

99.6 ± 73.1

0.65

Viral load (X106) (mean ± SD)

7.04 ± 8.02

6.76 ± 7.47

0.16

ESR 1st hour

52.2 ± 19.0

52.0 ± 16.7

0.78

NRS for pain (mean ± SD)

6.3 ± 2.9

6.2 ± 3.1

0.64

TJC (mean ± SD)

9.8 ± 9.4

10.2 ± 10.6

0.07

SJC (mean ± SD)

7.3 ± 7.9

7.3 ± 8.2

0.98

Morning stiffness (MS) (mean ± SD)

68.9 ± 22.7

68.5 ± 26.5

0.19

GSUS synovitis score (mean ± SD)

1.8 ± 0.8

1.9 ± 0.8

0.41

PDUS score (mean ± SD)

0.9 ± 0.8

0.9 ± 0.8

1.00

Pre-study medications, n (%)

Analgesics#

15 (75)

14 (70)

0.72

Steroid+

12 (60)

13 (65)

0.74

DMARDs*

9 (45)

11 (55)

0.52

  1. #Analgesics used were paracetamol and tramadol
  2. +Steroid dosage ranged from 5 to 20 mg/day
  3. *DMARDs used were sulfasalazine and cyclosporine
  4. RF rheumatoid factor, ESR erythrocyte sedimentation rate, NRS numerical rate scale, TJC tender joints count, SJC swollen joints count, MS duration of morning stiffness, GSUS grey scale ultrasound, PDUS Power Doppler ultrasound, DMARDs disease modifying anti-rheumatic drugs